The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy

NCT07039474 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-06-26

No results posted yet for this study

Summary

The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy

Conditions

  • Solid Tumors and Hematological Tumors

Interventions

DRUG

18F-G1

18F-G1 is injected intravenously with a dose of 0.06-0.08mCi/kg

Sponsors & Collaborators

  • Peking University First Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-15
Primary Completion
2026-12-31
Completion
2027-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07039474 on ClinicalTrials.gov